Not Yet RecruitingEarly Phase 1

BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

United States20 participantsStarted 2026-02-01

Plain-language summary

This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older. * Planning to undergo transplantation of the lung. * Willing and able to read, understand, and be capable of giving informed consent. * Use of ex vivo lung perfusion (EVLP) prior to lung transplant. Exclusion Criteria: * Previous or current use of IL-1R antagonist drug. * Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating, such as highly sensitized patients who require additional immunosuppression, multiorgan transplant, and re- transplant.

What they're measuring

Primary graft dysfunction after lung transplant

Timeframe: 3 days post lung transplant

Trial details

NCT IDNCT07410312

SponsorNorthwestern University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08

Contact for this trial

Mary Carns, MS

312-503-1137 m-carns@northwestern.edu

View on ClinicalTrials.gov More Lung Transplant Recipient trials